Determination of meloxicam in human plasma by HPLC

Authors

  • Valentina Porta Universidade de São Paulo; Faculdade de Ciências Farmacêuticas; Departamento de Farmácia
  • Humberto Gomes Ferraz Universidade de São Paulo; Faculdade de Ciências Farmacêuticas; Departamento de Farmácia
  • Tatiane Maria de Lima Souza Universidade de São Paulo; Faculdade de Ciências Farmacêuticas; Departamento de Farmácia
  • Eunice Kazue Kano Universidade de São Paulo; Faculdade de Ciências Farmacêuticas; Departamento de Farmácia
  • Cristina Helena dos Reis Serra Universidade de São Paulo; Faculdade de Ciências Farmacêuticas; Departamento de Farmácia

DOI:

https://doi.org/10.1590/S1516-93322005000200009

Keywords:

Meloxicam, Piroxicam, Plasma, HPLC

Abstract

A simple, rapid and specific high-performance liquid cromatographic (HPLC) method was developed and validated to estimate meloxicam (COX-2 inhibitor) levels in human plasma. Piroxicam was used as internal standard. Reversed phase chromatography was conducted using a Synergi RP-MAX (150 x 4.6 mm) column at 30 ºC and a mobile phase of acetonitrile and 0.025 mol/L pH 4,5 phosphate buffer (40:60, v/v), at a flow rate of 1mL/min. Analytes were detected at 364 nm. Plasma samples were acidified with 1 mol/L hydrochloric acid and extracted with tert-butyl methyl ether, evaporated to dryness, reconstituted in 250 mL of mobile phase and injected in the column. The retention time of meloxicam and piroxicam were 3.35 and 4.19 minutes, respectively. This method showed to be linear in the range of 50 - 4500 ng/mL (R² = 0.9995), a LOQ of 50 ng/mL and accuracy of 114%. The analytical method showed suitable specificity, sensitivity, linearity, precision and accuracy, and can be used in bioequivalence or pharmacokinetics studies involving meloxicam.

Downloads

Download data is not yet available.

Published

2005-06-01

Issue

Section

Original Papers

How to Cite

Determination of meloxicam in human plasma by HPLC. (2005). Revista Brasileira De Ciências Farmacêuticas, 41(2), 215-222. https://doi.org/10.1590/S1516-93322005000200009